A study led by Dr. Jizong Zhao, Dr. Dong Zhang, and Dr. Peicong Ge explores the role of glutamine in stroke risk for Moyamoya disease (MMD) patients. Elevated serum glutamine levels were linked to increased stroke risk in MMD. The study found that manipulating integrin subunit beta 4 (ITGB4) and using atorvastatin could alleviate the glutamine-induced endothelial-to-mesenchymal transition (EndMT), providing potential therapeutic targets for MMD. The study conducted in-depth investigations with HBMECs, revealing the direct impact of glutamine on cell behavior and suggesting ITGB4 and signaling pathways as promising therapeutic targets. Atorvastatin may have a new role in treating MMD, offering hope for improved patient care.
Source link
Elevated glutamine triggers stroke risk in moyamoya disease via endothelial‐to‐mesenchymal transition, finds study
